Search Within

Odette Marsinay Smith

Formats
  1. Meeting Abstract (62)
  2. Journal Article (36)
Groups
  1. Department of Medicine (97)
  2. Center for Hematologic Malignancies (95)
  3. Executive Committee, Center for Hematologic Malignancies (95)
  4. GSK Faculty (95)
  5. Hematologic Malignancies, Division of (95)
  6. Immunology Program Faculty (95)

More Groups

People
  1. Marcel Van Den Brink (95)
  2. Amanda Holland (47)
  3. Robert Jenq (46)
  4. Alan Hanash (38)
  5. David Suh (35)
  6. Jennifer Tsai (35)

More People

Years
  1. 2018 (6)
  2. 2017 (4)
  3. 2016 (2)
  4. 2015 (3)
  5. 2014 (6)
  6. 2013 (9)

More Years

Publications
  1. Blood (41)
  2. Biology of Blood and Marrow Transplantation (23)
  3. Journal of Immunology (4)
  4. Bone Marrow Transplantation (3)
  5. Journal of Clinical Investigation (3)
  6. Journal of Experimental Medicine (3)

More Publications

Publishers
  1. American Society of Hematology (41)
  2. Elsevier Inc. (25)
  3. Nature Publishing Group (8)
  4. The American Association of Immunologists, Inc (4)
  5. American Society for Clinical Investigation (3)
  6. Rockefeller University Press (3)

More Publishers

Results (98)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetically engineered donor T cells for BMT immunotherapy: Expression of trail and PLZF selectively enhances GVT and abrogates GVHD
    Meeting Abstract

    Ghosh, A.; Holland, A. M.; Dogan, Y.; Yim, N.; Rao, U. K.; Young, L. F.; Smith, O. M.; Jenq, R.; Na, I. K.; Tsai, J. J.; more...
    Biology of Blood and Marrow Transplantation (2011)

    Fulltext@MSK | Save
  • Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation
    Journal Article

    Lu, S. X.; Kappel, L. W.; Charbonneau Allard, A. M.; Atallah, R.; Holland, A. M.; Turbide, C.; Hubbard, V. M.; Rotolo, J. A.; Smith, M.; Suh, D.; more...
    PLoS ONE (2011)

    Fulltext@MSK | Save
  • Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL
    Journal Article

    Hanash, A. M.; Kappel, L. W.; Yim, N. L.; Nejat, R. A.; Goldberg, G. L.; Smith, O. M.; Rao, U. K.; Dykstra, L.; Na, I. K.; Holland, A. M.; more...
    Blood (2011)

    Fulltext@MSK | Save
  • TRAIL/DR5 interactions are important for mediating thymic damage after allogeneic bone marrow transplantation
    Meeting Abstract

    Lu, S. X.; Na, I. K.; Yim, N.; Goldberg, G. L.; Tsai, J.; Rao, U. K.; Smith, M.; King, C. G.; Suh, D.; Hirschorn-Cymerman, D.; more...
    Biology of Blood and Marrow Transplantation (2010)

    Fulltext@MSK | Save
  • P-selectin regulates leukocyte trafficking and experimental graft-versus-host-disease after allogeneic bone marrow transplantation
    Meeting Abstract

    Lu, S. X.; Palomba, M. L.; Na, I. K.; Terwey, T. H.; Alpdogan, O.; Bautista, J. L.; Smith, M.; Suh, D.; King, C. G.; Rao, U. K.; more...
    Biology of Blood and Marrow Transplantation (2010)

    Fulltext@MSK | Save
  • Over-expression of trail on donor T cells simultaneously ameliorates GVHD and enhances GVT
    Meeting Abstract

    Ghosh, A.; Holland, A. M.; Kappel, L. W.; Dogan, Y.; Yim, N.; Rao, U.; Smith, O. M.; Jenq, R. R.; Zakrzewski, J.; Na, I. K.; more...
    Biology of Blood and Marrow Transplantation (2010)

    Fulltext@MSK | Save
  • Abrogation of donor T cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD From GVL
    Meeting Abstract

    Hanash, A. M.; Kappel, L. W.; Yim, N. L.; Nejat, R. A.; Goldberg, G. L.; Smith, O. M.; Rao, U. K.; Dykstra, L.; Na, I. K.; Holland, A. M.; more...
    Blood (2010)

    Fulltext@MSK | Save
  • Genetic engineering of donor T cells for BMT immunotherapy: Expression of TRAIL and PLZF selectively enhances GVT and abrogates GVHD
    Meeting Abstract

    Ghosh, A.; Holland, A. M.; Dogan, Y.; Yim, N.; Rao, U. K.; Young, L. F.; Smith, O. M.; Jenq, R.; Na, I. K.; Tsai, J.; more...
    Blood (2010)

    Fulltext@MSK | Save
  • Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth
    Journal Article

    Penack, O.; Henke, E.; Suh, D.; King, C. G.; Smith, O. M.; Na, I. K.; Holland, A. M.; Ghosh, A.; Lu, S. X.; Jenq, R. R.; more...
    JNCI: Journal of the National Cancer Institute (2010)

    Fulltext@MSK | Save
  • The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease
    Journal Article

    Na, I. K.; Lu, S. X.; Yim, N. L.; Goldberg, G. L.; Tsai, J.; Rao, U.; Smith, O. M.; King, C. G.; Suh, D.; Hirschhorn-Cymerman, D.; more...
    Journal of Clinical Investigation (2010)

    Fulltext@MSK | Save